natgillin/translations-raw huggingface dataset:
- Never use a syringe to remove medicine from your pen. 
- Nikdar ne uporabite brizge za jemanje zdravila iz peresnika.
Pull off the pen cap. 
Snemite pokrovček peresnika.
After screening, eligible patients (n=1018) entered a 6 week run-in phase where patients remained on or switched to insulin glargine, in case they took another basal insulin, and had their insulin dose titrated/stabilised while continuing metformin (if previously taken). 
Med tem obdobjem so ostali na insulinu glargin oziroma so nanj prešli, če so prej uporabljali kakšen drug bazalni insulin, odmerek insulina pa so jim prilagajali/stabilizirali med nadaljnjo uporabo metformina (če so ga jemali že prej).
In parallel, glucagon secretion is suppressed. 
Vzporedno s tem zavre izločanje glukagona.
• A reminder on the need to report all medication errors with Suliqua will be part of the healthcare professional guide. 
• Del vodnika za zdravstvene delavce bo opozorilo, da je treba poročati o vseh napakah pri uporabi zdravila Suliqua.
The delay of gastric emptying with lixisenatide may reduce the rate of absorption of orally administered medicinal products. 
Upočasnitev praznjenja želodca zaradi liksisenatida lahko zmanjša hitrost absorpcije peroralno uporabljenih zdravil.
Suliqua (30-60) pen contains insulin glargine and lixisenatide. 
Injekcijski peresnik Suliqua (30-60) vsebuje insulin glargin in liksisenatid.
The insulin glargine/lixisenatide ratio has no relevant impact on the PK of insulin glargine and lixisenatide in Suliqua. 
Razmerje insulin glargin/liksisenatid nima pomembnega vpliva na farmakokinetiko insulina glargin in liksisenatida v zdravilu Suliqua.
• You lose carbohydrates from being sick (vomiting) or diarrhoea. 
• Izgubljate ogljikove hidrate zaradi bruhanja ali driske.
• You change the area where you inject Suliqua. 
• če zamenjate predel, kamor injicirate zdravilo Suliqua, npr. s stegna na nadlaket.
Figure - Mean HbA1c (%) at start of screening, at randomization, Each Time Point (Completers) and at Week 30 - mITT population 
Slika - Povprečni HbA1c (%) na začetku presejanja, ob randomizaciji, na vsaki časovni točki (bolniki, ki so dokončali študijo) in po 30 tednih (LOCF*) - populacija mZNZ
Gender has no clinically relevant effect on the pharmacokinetics of lixisenatide 
Spol nima klinično pomembnega vpliva na farmakokinetiko liksisenatida.
• Do not use a syringe to remove medicine from your pen. 
• Ne uporabite brizge za jemanje zdravila iz peresnika.
Always do a safety test before each injection to: 
Pred vsakim injiciranjem opravite varnostni preizkus:
• Do not use the pen if your single daily dose is less than 30 dose steps, shown as white numbers on a black background. 
• Ne uporabite tega peresnika, če je vaš enkratni dnevni odmerek manj kot 30 odmernih korakov (prikazano z belimi številkami na črnem ozadju).
Comparison versus lixisenatide [95% confidence interval]* 
Primerjava z liksisenatidom [95 % interval zaupanja]*
• Do not use the pen if your single daily dose is less than 10 dose steps, shown as white numbers on a black background. 
• Ne uporabite tega peresnika, če je vaš enkratni dnevni odmerek manj kot 10 odmernih korakov (prikazano z belimi številkami na črnem ozadju).
Cases of generalised allergic reaction including anaphylactic reaction and angioedema have been reported during marketed use of insulin glargine and lixisenatide. 
Med uporabo insulina glargin in liksisenatida po prihodu na trg so poročali o primerih generaliziranih alergijskih reakcij, vključno za anafilaktičnimi reakcijami in angioedemom.
• Never re-use needles. 
• Igel nikdar ne uporabljajte ponovno.
Non-clinical data for insulin glargine reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction. 
Predklinični podatki o insulinu glargin na osnovi običajnih študij farmakološke varnosti, toksičnosti pri ponavljajočih odmerkih, genotoksičnosti, kancerogenega potenciala in vpliva na sposobnost razmnoževanja ne kažejo posebnega tveganja za človeka.
What Suliqua contains 
Kaj vsebuje zdravilo Suliqua
• Do not store your pen with the needle attached. 
• Peresnika ne shranjujte z nameščeno iglo.
Preferably inject Suliqua before the same meal every day, when you have chosen the most convenient way. 
Ko ste izbrali čas injiciranja, ki vam najbolj ustreza, si zdravilo Suliqua po možnosti vsak dan injicirajte pred istim obrokom.
When administered 1 or 4 hours after 10 mcg lixisenatide, Cmax of paracetamol was decreased by 29% and 31%, respectively and median tmax was delayed by 2.0 and 1.75 hours, respectively. 
Če je bil paracetamol uporabljen 1 uro po injiciranju 10 mcg liksisenatida, se je Cmax paracetamola znižala za 29 %, njegov mediani tmax pa se je podaljšal za 2,0 uri; če je bil paracetamol uporabljen 4 ure po injiciranju, je bilo znižanje Cmax 31 % in podaljšanje tmax 1,75 ure.
See also section 2 “What you need to know before you use Suliqua” for information on sodium and metacresol. 
Za informacije o natriju in metakrezolu glejte tudi poglavje 2, "Kaj morate vedeti, preden boste uporabili zdravilo Suliqua".
• A reminder on the need to report all medication errors with Suliqua will be part of patient guide. 
• Del vodnika za bolnike bo opozorilo, da je treba poročati o vseh napakah pri uporabi zdravila Suliqua.
Do not stop using this medicine without talking to your doctor. 
Če ste prenehali uporabljati zdravilo Suliqua Ne prenehajte uporabljati tega zdravila, ne da bi se prej posvetovali z zdravnikom.
What to do if you experience hyperglycaemia 
Kaj storiti, če se pojavi hiperglikemija?
If your blood sugar is too high, follow the guidance for hyperglycaemia (see information in the box at the end of this leaflet). 
Če imate previsok krvni sladkor, upoštevajte navodila za ravnanje v primeru hiperglikemije (glejte informacije v okvirju na koncu tega navodila za uporabo).
• Pharmacists are encouraged to check that patients and caretakers are able to read the strength of Suliqua, the dose range of the pre filled pen and the dose counter of the pre filled pen before dispensing insulin glargine/lixisenatide. 
• Preden farmacevti izdajo insulin glargin/liksisenatid, naj preverijo, ali bolniki in negovalci zmorejo prebrati jakost zdravila Suliqua, razpon odmerkov napolnjenega injekcijskega peresnika in števec odmerkov na peresniku.
As a peptide, lixisenatide is eliminated through glomerular filtration, followed by tubular reabsorption and subsequent metabolic degradation, resulting in smaller peptides and amino acids, which are reintroduced in the protein metabolism. 
Liksisenatid je peptid in se tako izloča z glomerularno filtracijo, ki jih sledi tubularna reabsorpcija in nato presnovna razgradnja.
• Do not reuse needles. 
• Igel ne uporabljajte ponovno.
Do not use Suliqua: 
Ne uporabljajte zdravila Suliqua
• Never use a syringe to remove medicine product from your pen. 
• Nikdar ne uporabite brizge za jemanje zdravila iz peresnika.
Do not inject a dose greater than 60 dose steps. 
Ne injicirajte odmerkov, večjih od 60 odmernih korakov.
• Change the needle (see STEP 6 Remove the needle and STEP 2 Attach a new needle) then do a safety test (see STEP 3). 
KORAK, Namestite novo iglo), potem opravite varnostni preizkus (glejte 3.
Do not store with attached needle. 
Ne shranjujte z nameščeno iglo.
For dose steps from 30-60 units, Suliqua 100 units/ml + 33 micrograms/ml solution for injection in a pre-filled pen is available. 
Za odmerne korake od 30 do 60 enot je na voljo zdravilo Suliqua 100 enot/ml + 33 mikrogramov/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku SoloStar.
Suliqua (10-40) pen contains insulin glargine and lixisenatide. 
Injekcijski peresnik Suliqua (10-40) vsebuje insulin glargin in liksisenatid.
• The other ingredients are: 85% glycerol, methionine, metacresol, zinc chloride, concentrated hydrochloric acid, and sodium hydroxide (for pH adjustement) and water for injections. 
• Druge sestavine so: 85 % glicerol, metionin, metakrezol, cinkov klorid, koncentrirana klorovodikova kislina in natrijev hidroksid (za prilagoditev pH) in voda za injekcije.
Number of subjects (mITT) 
Izhodiščno (povprečje)
Each pen contains 3 ml of solution for injection, equivalent to 300 units insulin glargine and 100 micrograms lixisenatide. 
En peresnik vsebuje 3 ml raztopine za injiciranje; to ustreza 300 enotam insulina glargin in 100 mikrogramom liksisenatida.
No pharmacokinetic interactions are known for insulin glargine. 
Za insulin glargin ni znanih farmakokinetičnih medsebojnih delovanj.
• Suliqua 100 units/ml + 50 micrograms/ml pre-filled pen delivers dose steps from 10-40 units of insulin glargine in combination with 5-20 mcg lixisenatide (Suliqua (10-40) pen). 
• Napolnjeni injekcijski peresnik Suliqua 100 enot/ml + 50 mikrogramov/ml zagotavlja odmerne korake 10-40 enot insulina glargin v kombinaciji s 5-20 mcg liksisenatida (peresnik Suliqua
Insulin glargine 
Insulin glargin
Age has no clinically relevant effect on the pharmacokinetics of lixisenatide. 
Starost ni klinično pomembno vplivala na farmakokinetiko liksisenatida.
The primary activity of insulin, including insulin glargine, is regulation of glucose metabolism. 
Temeljno delovanje insulina je uravnavanje presnove glukoze; to velja tudi za insulin glargin.
• Read the instructions in your package leaflet carefully before using Suliqua. 
• Pred uporabo zdravila Suliqua natančno preberite navodila, navedena v navodilu za uporabo zdravila.
Warnings and precautions Talk to your doctor, pharmacist or nurse before using Suliqua if: 
Opozorila in previdnostni ukrepi Pred začetkom uporabe zdravila Suliqua se posvetujte z zdravnikom, farmacevtom ali medicinsko sestro:
• Suliqua 100 units/ml + 33 micrograms/ml pre-filled pen delivers dose steps from 30-60 units of insulin glargine in combination with 10-20 mcg lixisenatide (Suliqua (30-60) pen). 
• Napolnjeni injekcijski peresnik Suliqua 100 enot/ml + 33 mikrogramov/ml zagotavlja odmerne korake 30-60 enot insulina glargin v kombinaciji z 10-20 mcg liksisenatida (peresnik Suliqua
Ethnic origin had no clinically relevant effect on the pharmacokinetics of lixisenatide based on the results of pharmacokinetic studies in Caucasian, Japanese and Chinese subjects. 
Glede na farmakokinetične študije pri belcih, Japoncih in Kitajcih etnično poreklo ni klinično pomembno vplivalo na farmakokinetiko liksisenatida.
It is not known if Suliqua harms your unborn child. Suliqua should not be used if breast-feeding. 
Ni znano, ali zdravilo Suliqua škoduje nerojenemu otroku.
Reversible testicular and epididymal lesions were seen in dogs treated with lixisenatide. 
Pri psih, ki so prejemali liksisenatid, so ugotovili reverzibilne lezije mod in obmodka.
LIST OF EXCIPIENTS glycerol 85%, methionine, metacresol (see leaflet for further information), zinc chloride, concentrated hydrochloric acid and sodium hydroxide (for pH adjustment), water for injections. 
85 % glicerol, metionin, metakrezol (za dodatne informacije glejte navodilo za uporabo), cinkov klorid, koncentrirana klorovodikova kislina in natrijev hidroksid (za prilagoditev pH) in voda za injekcije.
N Documented symptomatic hypoglycaemia* Patients with event, n (%) 120 (25.6%) 110 (23.6%) 15 (6.4%) 146 (40.0) 155 (42.5) 
N Dokumentirana simptomatska hipoglikemija* Bolniki z dogodkom, n (%) Dogodkov na bolnik-leto, n 1,44 Huda hipoglikemija** Dogodkov na bolnik-leto, n
Switch from basal insulin 
Prehod z bazalnega insulina
The effect of some medicines you swallow might be affected by Suliqua. 
Zdravilo Suliqua lahko vpliva na učinek nekaterih zdravil, ki jih zaužijete.
If your blood sugar is too low, follow the guidance for hypoglycaemia (see information in the box at the end of this leaflet). 
Če imate prenizek krvni sladkor, upoštevajte navodila za ravnanje v primeru hipoglikemije (glejte informacije v okvirju na koncu tega navodila za uporabo).
• Contact your doctor straight away if you have severe hyperglycaemia or ketoacidosis. 
• Če imate hudo hiperglikemijo ali ketoacidozo, se takoj posvetujte z zdravnikom.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Suliqua 100 units/mL +33 mcg/mL solution for injection insulin glargine + lixisenatide 
IME ZDRAVILA IN POT(I) UPORABE Suliqua 100 enot/ml + 33 mcg/ml injekcija insulin glargin + liksisenatid subkutana uporaba
Do not inject a dose higher than 40 dose steps. 
Ne injicirajte odmerkov, večjih od 40 odmernih korakov.
Patients [n (%)] reaching HbA1c <7% at week 30* Fasting plasma glucose (mmol/L) Baseline (mean) 
Število bolnikov (%), ki so 30. teden dosegli HbA1c < 7 %* Glukoza v plazmi na tešče (mmol/l) Izhodiščno (povprečje) Na koncu študije (povprečje) Sprememba od izhodišča (po metodi NK), povprečje
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Suliqua 100 units/mL + 50 mcg/mL solution for injection insulin glargine + lixisenatide 
IME ZDRAVILA IN POT(I) UPORABE Suliqua 100 enot/ml + 50 mcg/ml injekcija insulin glargin + liksisenatid subkutana uporaba
See table and figure below for the other endpoints in the study. 
Za druge opazovane dogodke v študiji glejte preglednico in sliko spodaj.
(such as acetylsalicylic acid). 
propoksifen ali salicilate (na primer acetilsalicilno kislino).
Baseline (mean; post run-in phase) End of treatment (mean) 
Izhodiščno (povprečje, po obdobju uvajanja) Na koncu zdravljenja (povprečje)
In patients with renal impairment, however, insulin requirements may be diminished due to reduced insulin metabolism. 
Vendar se lahko bolnikom z okvaro ledvic potreba po insulinu zmanjša zaradi zmanjšane presnove insulina.
Do not inject a dose lower than 30 dose steps. 
Ne injicirajte odmerkov, manjših od 30 odmernih korakov.
Proportion difference vs. lixisenatide [95% confidence interval]* 
z liksisenatidom [95 % interval zaupanja]*
No dose adjustment is required for lixisenatide in patients with mild or moderate renal impairment. 
Bolnikom z blago ali zmerno okvaro ledvic odmerka liksisenatida ni treba prilagoditi.
Do not inject a dose lower than 10 dose steps. 
Ne injicirajte odmerkov, manjših od 10 odmernih korakov.
Your blood sugar level may either rise or fall if you drink alcohol. 
Če pijete alkohol, se vam lahko krvni sladkor zniža ali zviša.
If you have injected too much of this medicine, your blood sugar level may become too low (hypoglycaemia). 
Če ste uporabili večji odmerek zdravila Suliqua, kot bi smeli Če ste si injicirali preveč zdravila, se vam lahko koncentracija krvnega sladkorja preveč zniža (hipoglikemija).
• a sharps container for used needles and pens. 
• vsebnik za ostre odpadke za uporabljene igle in peresnike (glejte Kako zavreči peresnik).
Patients screened had type 2 diabetes were treated with basal insulin for at least 6 months, receiving a stable daily dose of between 15 and 40 U alone or combined with 1 or 2 OADs (metformin or a sulfonylurea or a glinide or a SGLT-2 inhibitor or a DPP-4 inhibitor), had an HbA1c between 7.5% and 10% (mean HbA1c of 8.5% at screening) and a FPG less than or equal to 10.0 mmol/L or 11.1 mmol/L depending on their previous anti-diabetic treatment. 
Za zdravljenje so vsaj 6 mesecev uporabljali bazalni insulin v stabilnem dnevnem odmerku od 15 do 40 enot, samega ali v kombinaciji z 1 ali 2 POAD (metformin ali sulfonilsečnina ali glinid ali zaviralec SGLT-2 ali zaviralec DPP-4).
• Thyroid hormones, for thyroid gland problems. 
• Ščitnične hormone, za težave s ščitnico.
• Cold, runny nose, sore throat 
• prehlad, izcedek iz nosu, vnetje žrela
Each pen contains 3 ml of solution 
En peresnik vsebuje 3 ml raztopine.
The differentiation between the pen strengths is based on the dose range of the pen. 
Jakosti peresnikov se razlikujeta po razponu odmerkov enega in drugega peresnika.
2 hour PPG (mmol/L)** Baseline (mean) End of study (mean) 
PPG - 2 uri (mmol/l)** Izhodiščno (povprečje) Na koncu študije (povprečje) Sprememba od izhodišča (po metodi NK) Sprememba v prim.
30 dose steps (30 units/10 mcg)* * units insulin glargine (100 units/ml) / mcg lixisenatide 
*enot insulina glargin (100 enot/ml) / mcg liksisenatida
• Each dose step you dial contains 1 unit of insulin glargine and 0.5 micrograms of lixisenatide. 
• Vsak odmerni korak, ki ga nastavite, vsebuje 1 enoto insulina glargin in 0,5 mikrograma liksisenatida.
STEP 2: Attach a new needle 
KORAK, Namestite novo iglo),
Always keep the cap on the pen when you are not using it in order to protect it from light. 
Kadar peresnika ne uporabljate, naj ima vedno nameščen pokrovček za zagotovitev zaščite pred svetlobo.
Previous therapy 
Predhodno zdravljenje
Speak to a doctor straight away if you are not able to control the hypoglycaemia, or it comes back again. 
Če hipoglikemije ne morete obvladati ali se ponovi, se takoj posvetujte z zdravnikom.
• in a vein. 
• Za injiciranje v veno.
A. Grip the widest part of the outer needle cap. Keep the needle straight and guide it into the outer needle cap back. 
Držite iglo naravnost in jo usmerite nazaj v zunanji pokrovček igle.
Fatigue Injection site reactions 
Splošne težave in spremembe na mestu aplikacije utrujenost reakcije na mestu injiciranja
LS difference versus lixisenatide (mean) [95%CI] (p-value) 
z liksisenatidom (po metodi NK), povprečje [95 % IZ] (vrednost p)
5x 3 mL pens 
5x 3 ml injekcijski peresniki
• Do not use this pen if you need a daily dose less than 30 dose steps or if you need more than 60 dose steps. 
• Ne uporabljajte tega peresnika, če potrebujete dnevni odmerek, manjši od 30 odmernih korakov ali večji od 60 odmernih korakov.
• Store the pen with your pen cap on. 
• Peresnik shranjujte z nameščenim pokrovčkom.
Suliqua 100 units/ml + 33 micrograms/ml solution for injection in a pre-filled pen Insulin glargine + lixisenatide 
Suliqua 100 enot/ml + 33 mikrogramov/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku insulin glargin + liksisenatid
Suliqua 100 units/ml + 50 micrograms/ml solution for injection in a pre-filled pen Insulin glargine + lixisenatide 
Suliqua 100 enot/ml + 50 mikrogramov/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku insulin glargin + liksisenatid
Proportion difference versus insulin glargine [95% confidence interval] (p-value) 
Razlika v primerjavi z insulinom glargin [95 % interval zaupanja] (vrednost p)
Suliqua is an injectable diabetes medicine that contains two active substances: 
• Zdravilo Suliqua je na voljo v dveh napolnjenih injekcijskih peresnikih, ki vsebujeta dve različni jakosti liksisenatida in različna razpona odmerkov:
60 dose steps. 
KORAK in 2.
• Do not use this pen if you need a daily dose less than 10 dose steps or if you need more than 40 dose steps. 
• Ne uporabljajte tega peresnika, če potrebujete dnevni odmerek, manjši od 10 odmernih korakov ali večji od 40 odmernih korakov.
Handle your pen with care • If you think that your pen may be damaged, do not try to fix it. Use a new one. 
• Če menite, da je peresnik pokvarjen, ga ne poskušajte popraviti.
Each dose step of Suliqua contains 1 unit of insulin glargine and 0.5 micrograms of lixisenatide,. 
En odmerni korak zdravila Suliqua vsebuje 1 enoto insulina glargin in 0,5 mikrogramov liksisenatida.
• Do not use this pen if you need a single daily dose that is less than 10 dose steps, or more than 40 dose steps. 
• Peresnika ne uporabljajte, če potrebujete samo en dnevni odmerek, ki je manjši od 10 odmernih korakov ali večji od 40 odmernih korakov.
• Explain to your patient that: You are prescribing a number of dose steps which corresponds to a set number of units of insulin plus a fixed amount lixisenatide For Suliqua, one dose step always contains one unit of insulin, regardless of the Suliqua pre filled pen being used (10-40 pen or 30 60 pen) The dose counter of the pen device shows the number of dose steps to be injected, 
• Pri zdravilu Suliqua en odmerni korak vedno vsebuje eno enoto insulina, ne glede na to, kateri napolnjeni injekcijski peresnik zdravila Suliqua je uporabljen (peresnik 10-40 ali peresnik
Each dose step contains 1 unit of insulin glargine and 0.33 micrograms of lixisenatide. 
En odmerni korak vsebuje 1 enoto insulina glargin in 0,33 mikrogramov liksisenatida.
Each ml contains 100 units of insulin glargine and 33 micrograms lixisenatide. 
En mililiter vsebuje 100 enot insulina glargin in 33 mikrogramov liksisenatida.
10x 3 mL pens 
10x 3 ml injekcijski peresniki
Suliqua 100 units/ml + 50 micrograms/ml solution for injection in a pre-filled pen 
Suliqua 100 enot/ml + 50 mikrogramov/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
• For total daily doses >60 dose steps/day, Suliqua must not be used. 
• Zdravila Suliqua se ne sme uporabljati za celotne dnevne odmerke, večje od 60 odmernih korakov na dan.
• Each dose step of Suliqua you dial contains 1 unit of insulin glargine and 0.33 micrograms of lixisenatide. 
• Vsak odmerni korak zdravila Suliqua, ki ga nastavite, vsebuje 1 enoto insulina glargin in 0,33
Each mL contains 100 units of insulin glargine and 50 micrograms lixisenatide. 
En mililiter vsebuje 100 enot insulina glargin in 50 mikrogramov liksisenatida.
Talk to your doctor beforeGarling. 
S peresnikom ravnaje previdno.
How to store Suliqua 
Shranjevanje zdravila Suliqua
Concentrated hydrochloric acid (for pH adjustment) Sodium hydroxide (for pH adjustment) Water for injections 
85 % glicerol metionin metakrezol cinkov klorid koncentrirana klorovodikova kislina (za prilagoditev pH) natrijev hidroksid (za prilagoditev pH) voda za injekcije
Proportion difference vs. insulin glargine [95% confidence interval] (p-value) 
Primerjava z insulinom glargin [95 % interval zaupanja] (vrednost p)
Dizziness 
Stegna
Each dose step contains 1 unit of insulin glargine and 0.5 micrograms of lixisenatide. 
En odmerni korak vsebuje 1 enoto insulina glargin in 0,5 mikrogramov liksisenatida.
Suliqua 
Peresnik Suliqua
Each pen contains 300 units of insulin glargine and 150 micrograms lixisenatide in 3 ml solution. 
En peresnik vsebuje 300 enot insulina glargin in 150 mikrogramom liksisenatida v 3 ml raztopine.
• Do not use the pen if the medicine looks cloudy, coloured or contains particles. 
• Če je zdravilo motno, obarvano, ali so v njem delci, peresnika ne uporabite.
• Suliqua is available in two pre filled pens containing different strengths of lixisenatide, and different dose ranges: Both pre filled pens contain insulin glargine in a strength of 100 units/ml Suliqua 10-40 pen allows daily doses between 10 and 40 dose steps of Suliqua to be given (strength: insulin glargine 100 units/ml and lixisenatide 50 mcg/ml; dose range: 10 to 40 units of insulin glargine in combination with 5 to 20 mcg lixisenatide) Suliqua 30-60 pen allows daily doses between 30 and 60 dose steps of Suliqua to be given (strength: insulin glargine 100 units/ml and lixisenatide 33 mcg/ml; dose range: 30 to 60 units insulin glargine in combination with 10 to 20 mcg lixisenatide) 
Injekcijski peresnik Suliqua 30-60 omogoča dajanje zdravila Suliqua v dnevnih odmerkih od 30 do 60 odmernih korakov (jakost: insulin glargin 100 enot/ml in liksisenatid 33 mcg/ml; razpon odmerkov: od 30 do 60 enot insulina glargina v kombinaciji z 10 do 20 mcg liksisenatida).
3x 3 mL pens 
3x 3 ml injekcijski peresniki
- Keep this leaflet. 
Pokrovček trdno namestite.
Lixisenatide Suliqua Insulin glargine 
Bolniki, ki še niso prejemali insulina Prehod z bazalnega insulina zdravilo Suliqua insulin glargin liksisenatid zdravilo Suliqua insulin glargin
Suliqua 100 units/ml + 33 micrograms/ml solution for injection in a pre-filled pen INSTRUCTIONS FOR USE 
Suliqua 100 enot/ml + 33 mikrogramov/ml raztopina za injiciranje v napolnjenem injekcijskem peresniku
Plunger* Dose window Dose pointer 
Okence odmerka Kazalnik odmerka
Each pen contains 300 units of insulin glargine and 100 micrograms lixisenatide in 3 mL solution. 
En injekcijski peresnik vsebuje 300 enot insulina glargin in 100 mikrogramov liksisenatida v 3 ml raztopine.
Each pen contains 300 units insulin glargine and 150 micrograms lixisenatide in 3 ml of solution. 
En injekcijski peresnik vsebuje 300 enot insulina glargin in 150 mikrogramov liksisenatida v 3 ml raztopine.
• Make sure that you get the correct dose. 
• da boste zagotovili injiciranje pravilnega odmerka.
Nausea Diarrhoea Vomiting 
Bolezni imunskega sistema urtikarija